INTRODUCTION AND OBJECTIVES: Use of partial nephrectomy for clinical T3a renal mass (cT3aRM) is controversial. We sought to evaluate the quality outcomes of robot-assisted partial nephrectomy (RAPN).
METHODS: Retrospective multicenter and multinational analysis of patients with nonmetastatic cT3a renal mass [RObotic SUrgery for LArge renal mass (ROSULA) Group]. Patient demographics, tumor characteristics, perioperative variables, renal functional data and pathological outcomes were analyzed. Primary endpoint was Trifecta, a composite quality outcome defined as negative surgical margin, warm ischemia time (WIT) 25 min, and no perioperative complications. "Optimal outcome" was define as achievement of Trifecta and !90% estimated glomerular filtration rate (eGFR) preservation and no chronic kidney disease (CKD) stage upgrading. Multivariable analysis (MVA) was used to identify risk factors associated lack of 'optimal outcome' achievement. RESULTS: A total of 100 patients with median age 60 respectively; 94 (94%) had negative margins. Intra-and postoperative complications were noted in 11 (11%) patients for each category, while 8 (8%) had major (Clavien-Dindo grade 3-5) complications. Median DeGFR was 8 ml/min/1.72m2, with !90% eGFR preservation noted in 52%. Trifecta rate was 64% and 41% achieved optimal outcome. MVA for factors associated with failure to achieve optimal outcome revealed increasing RENAL nephrometry score (OR 1.19, p[0.027) , decreasing preoperative eGFR (OR 1.16, p[0.002) , and increasing estimated blood loss (OR 1.05, p[0.038) as independent risk factors (Table) .
CONCLUSIONS: RAPN for select cT3aRM is feasible and safe, with acceptable quality outcomes. Further investigation is requisite to delineate role in management of cT3a disease. METHODS: The National Cancer Database was queried to identify 27,102 patients that underwent MIS-PN for cT1-2N0-M0 kidney cancer or MIS-RN for a cT1-4N0-1M0-1 kidney cancer from 2010-2014. Multivariable binary logistic regression models were used to identify predictors of patient, tumor, hospital and surgery specific variables associated with conversion from MIS to open surgery.
Source of
RESULTS: The rate of conversion to from MIS to open surgery was found to be 3.0% (n[777) for PN and 5.5% (n[1,314) for RN (Table I) METHODS: Using SEER e Medicare data, we identified patients over 65 with unilateral, clinical stage T1N0M0, non-urothelial kidney cancer who underwent surgical excision (i.e., radical or partial nephrectomy) as initial treatment between 2004 and 2013. After stratifying the cohort based on whether surgery was open or MIS, we evaluated for an association between approach and four outcomes: overall and cancer-specific survival, rates of second kidney cancer surgery, and rates of post-operative systemic cancer therapy. Regression was used to account for differences across study groupseincluded covariates: histologic sub-type, grade, radical versus partial nephrectomy, receipt of second treatment, year, Charlson comorbidity, and age at diagnosis. RESULTS: 5,150 patients met criteria for cohort inclusion. 3,062 (59.5%) underwent MIS. Cox-regression demonstrated no differences in overall or cancer-specific survival associated with surgical approach (HR[1.02, 95% CI 0.91-1.14 and HR[1.00 95% CI 0.87-1.15, respectively; open surgery [ reference group). Kaplan-Meier analyses showed no differences in rate of second surgery, however recipients of MIS were more likely to receive systemic cancer therapy (Figure) . Importantly, the association between MIS and increased receipt of systemic therapy persisted after adjusting for covariates (HR[1.32; 95% CI 1.09-1.59; p[0.005).
CONCLUSIONS: Among patients with T1 kidney cancer, surgical approach (open vs. MIS) was not associated with differences in overall survival, cancer-specific survival, or receipt of second cancer surgery, however, those receiving MIS were more likely to receive systemic cancer therapy post-operatively. As systemic therapy is typically reserved for patients with disease recurrence, this may indicate an important difference in cancer-specific outcomes attributable to surgical approach.
